Oral Formulation of Invega Sustenna
The oral formulation of Invega Sustenna (paliperidone palmitate long-acting injectable) is Invega (paliperidone extended-release tablets). 1
Key Information
Invega Sustenna is the long-acting injectable (LAI) formulation, while Invega is the oral extended-release tablet formulation—both contain the same active ingredient, paliperidone. 1, 2
Formulation Details
Oral Invega (Paliperidone ER):
- Available as extended-release tablets using OROS (Oral Osmotic System) technology 3
- Formulated for once-daily oral administration 4, 3
- The extended-release design minimizes plasma level fluctuations and allows treatment initiation at clinically effective doses without titration 3
Injectable Invega Sustenna:
- Contains paliperidone palmitate as a nanocrystal aqueous suspension 2
- Administered monthly via intramuscular injection (deltoid or gluteal) 2
- The palmitate ester hydrolyzes to release the active moiety, paliperidone 1
Clinical Relationship
Both formulations contain paliperidone, which is the major active metabolite of risperidone 1, 2. The key difference is the delivery system:
- Oral tablets provide daily dosing with extended-release kinetics 3
- Injectable suspension provides monthly dosing with sustained release over approximately 4 weeks 2
Important Distinction
Paliperidone (9-hydroxyrisperidone) is chemically distinct from its parent compound risperidone, with differences in metabolism (predominantly renal vs. hepatic), protein binding, and drug interaction potential 3. However, both the oral and injectable formulations deliver the same active antipsychotic agent—paliperidone.